Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study (vol 393, pg 2303, 2019)

Smolen J. S.; Pangan A. L.; Emery P.

首页> 外文期刊>The Lancet >Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study (vol 393, pg 2303, 2019)

【24h】

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study (vol 393, pg 2303, 2019)

机译：upadacitinib作为有活性类风湿性关节炎患者的单一疗法，对甲氨蝶呤的反应不足（选择单一疗法）：随机，安慰剂控制，双盲期3研究（Vol 393，PG 2303,2019）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2019年第10191期|共1页
作者
Smolen J. S.; Pangan A. L.; Emery P.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study (vol 393, pg 2303, 2019) [J] . Smolen J. S., Pangan A. L., Emery P. The Lancet . 2019,第10191期

机译：upadacitinib作为有活性类风湿性关节炎患者的单一疗法，对甲氨蝶呤的反应不足（选择单一疗法）：随机，安慰剂控制，双盲期3研究（Vol 393，PG 2303,2019）
2. Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study [J] . Bi L., Li Y., He L., Clinical and experimental rheumatology . 2019,第2期

机译：Certolizumab Pegol与甲氨蝶呤在甲氨蝶呤 - 不足的响应者中的抑制剂的疗效和安全性 - 活性类风湿性关节炎患者：24周的随机，双盲，安慰剂控制第3期研究
3. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial [J] . Burmester Gerd R., Kremer Joel M., Van den Bosch Filip, The Lancet . 2018,第10139期

机译：upadacitinib在类风湿性关节炎患者中的安全性和疗效和对常规合成疾病改性抗风湿药物的反应不足（选择 - 下一步）：随机，双盲，安慰剂控制第3期试验
4. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III multi-centre randomised double-blind placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate [O] . M Schiff, M Keiserman, C Codding, -1

机译：Abatacept或英夫利昔单抗与安慰剂在ATTEST中的疗效和安全性：类风湿关节炎患者对甲氨蝶呤反应不足的III期多中心随机双盲安慰剂对照研究
5. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate [O] . Schiff, M, Keiserman, M, Codding, C, 2008

机译：Abatacept或英夫利昔单抗与安慰剂在ATTEST中的疗效和安全性：类风湿关节炎患者对甲氨蝶呤反应不足的III期，多中心，随机，双盲，安慰剂对照研究

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study (vol 393, pg 2303, 2019)

著录项

相似文献

相关主题

期刊订阅